Rie Sakakibara1, Kentaro Inamura2, Yuichi Tambo3, Hironori Ninomiya2, Satoru Kitazono3, Noriko Yanagitani3, Atsushi Horiike3, Fumiyoshi Ohyanagi3, Yosuke Matsuura3, Masayuki Nakao3, Mingyon Mun3, Sakae Okumura3, Naohiko Inase4, Makoto Nishio3, Noriko Motoi5, Yuichi Ishikawa6. 1. Division of Pathology, The Cancer Institute, Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan. 2. Division of Pathology, The Cancer Institute, Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. 3. Thoracic Oncology Center, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. 4. Department of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan. 5. Division of Pathology, The Cancer Institute, Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan. 6. Division of Pathology, The Cancer Institute, Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: ishikawa@jfcr.or.jp.
Abstract
BACKGROUND: Because most lung cancers are diagnosed at advanced stages, we are forced to conduct molecular testing using small biopsy samples. Endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) is emerging as a minimally invasive biopsy technique. Here, we examined the usefulness of EBUS-TBNA to evaluate programmed death-ligand 1 (PD-L1) expression in lung cancer. METHODS: Using 97 consecutive cases of lung cancer diagnosed by EBUS-TBNA, from which 20 transbronchial biopsy (TBB) samples were available, we evaluated the number and morphological intactness of tumor cells in EBUS-TBNA and TBB samples. Additionally, given the intratumoral heterogeneity in primary lesions and the small sample size of biopsies, we also compared the tumor PD-L1 expression between the biopsy samples and the corresponding surgical materials. RESULTS: EBUS-TBNA collected a significantly larger number of tumor cells than TBB (P < .001); the median number (interquartile range) of cells was 1149 (379-3334) in EBUS-TBNA and 435 (218-1085) in TBB. The crush rate in EBUS-TBNA was significantly lower than in TBB (P < .001). These showed the excellence of EBUS-TBNA. Additionally, PD-L1 positivity of EBUS-TBNA showed a good concordance with the corresponding primary tumor (r = 0.75; P = .086; n = 6) as well as with lymph node metastasis (r = 0.93; P = .02; n = 5). Moreover, PD-L1 positivity between EBUS-TBNA and TBB (n = 16), TBB and the corresponding primary tumor (n = 41), and lymph node metastasis and the corresponding primary tumor (n = 47) showed a moderate correlation (all r > 0.48; all P < .001), strengthening the potential concordance between EBUS-TBNA and primary tumor in PD-L1 positivity. CONCLUSION: Our study suggests EBUS-TBNA as a promising method to evaluate PD-L1 expression in lung cancer.
BACKGROUND: Because most lung cancers are diagnosed at advanced stages, we are forced to conduct molecular testing using small biopsy samples. Endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) is emerging as a minimally invasive biopsy technique. Here, we examined the usefulness of EBUS-TBNA to evaluate programmed death-ligand 1 (PD-L1) expression in lung cancer. METHODS: Using 97 consecutive cases of lung cancer diagnosed by EBUS-TBNA, from which 20 transbronchial biopsy (TBB) samples were available, we evaluated the number and morphological intactness of tumor cells in EBUS-TBNA and TBB samples. Additionally, given the intratumoral heterogeneity in primary lesions and the small sample size of biopsies, we also compared the tumorPD-L1 expression between the biopsy samples and the corresponding surgical materials. RESULTS:EBUS-TBNA collected a significantly larger number of tumor cells than TBB (P < .001); the median number (interquartile range) of cells was 1149 (379-3334) in EBUS-TBNA and 435 (218-1085) in TBB. The crush rate in EBUS-TBNA was significantly lower than in TBB (P < .001). These showed the excellence of EBUS-TBNA. Additionally, PD-L1 positivity of EBUS-TBNA showed a good concordance with the corresponding primary tumor (r = 0.75; P = .086; n = 6) as well as with lymph node metastasis (r = 0.93; P = .02; n = 5). Moreover, PD-L1 positivity between EBUS-TBNA and TBB (n = 16), TBB and the corresponding primary tumor (n = 41), and lymph node metastasis and the corresponding primary tumor (n = 47) showed a moderate correlation (all r > 0.48; all P < .001), strengthening the potential concordance between EBUS-TBNA and primary tumor in PD-L1 positivity. CONCLUSION: Our study suggests EBUS-TBNA as a promising method to evaluate PD-L1 expression in lung cancer.
Authors: C Kuempers; L I S van der Linde; M Reischl; W Vogel; F Stellmacher; M Reck; D Heigener; K F Rabe; J Kirfel; S Perner; L Welker Journal: Virchows Arch Date: 2019-08-07 Impact factor: 4.064
Authors: Elliot B Levy; Maria I Fiel; Stanley R Hamilton; David E Kleiner; Shannon J McCall; Peter Schirmacher; William Travis; Michael D Kuo; Robert D Suh; Alda L Tam; Shaheen U Islam; Katherine Ferry-Galow; Rebecca A Enos; James H Doroshow; Hala R Makhlouf Journal: J Clin Oncol Date: 2020-03-05 Impact factor: 44.544
Authors: Maria-Rosa Ghigna; Adrian Crutu; Valentina Florea; Séverine Feuillet-Soummer; Pierre Baldeyrou; Julien Adam; Ludovic Lacroix; Benjamin Besse; Olaf Mercier; Elie Fadel; Peter Dorfmuller; Rida El Ayoubi; Vincent Thomas de Montpréville Journal: J Thorac Dis Date: 2018-07 Impact factor: 2.895
Authors: Vanda F Torous; Deepa Rangachari; Benjamin P Gallant; Meghan Shea; Daniel B Costa; Paul A VanderLaan Journal: J Am Soc Cytopathol Date: 2018-02-16
Authors: Mohammed S I Mansour; Kajsa Ericson Lindquist; Tomas Seidal; Ulrich Mager; Rikard Mohlin; Lena Tran; Kim Hejny; Benjamin Holmgren; Despoina Violidaki; Katalin Dobra; Annika Dejmek; Maria Planck; Hans Brunnström Journal: Acta Cytol Date: 2021-07-07 Impact factor: 2.319